NCT00511940已完成2 期
Acamprosate in the Treatment of Binge-Eating Disorder
Lindner Center of HOPE1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2007年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- The primary efficacy variable will be change in weekly binge frequency
研究概览
简要总结
The purpose of this research study is to determine the efficacy (how well it works), tolerability and safety of acomprosate compared with placebo in patients with binge eating disorder.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects will meet the DSM-IV (1) criteria for a diagnosis of binge eating disorder (BED) for at least the last 6 months. The DSM-IV criteria are as follows:
- •Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following: eating, in a discrete period of time (eg, within any two hour period), an amount of food that is definitely larger than most people would eat in a similar period of time under similar conditions; and a sense of lack of control over eating during the episode (eg, a feeling that one cannot stop eating or control what or how much one is eating).
- •The binge eating episodes are associated with at least three of the following: eating much more rapidly than normal; eating until uncomfortably full; eating large amounts of food when not feeling physically hungry; eating alone because of being embarrassed by how much one is eating; feeling disgusted with oneself, depressed, or feeling very guilty after overeating.
- •Marked distress regarding binge eating.
- •The binge eating occurs, on average, at least two days a week for six months.
- •The episodes of binge eating do not occur exclusively during the course of bulimia nervosa or anorexia nervosa.
- •In addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization
- •Weight > 85% of the midpoint of ideal body weight for their height. (According to the Metropolitan Height/Weight table.) The subject population is expected to include both normal weight and obese individuals (although the majority of subjects are expected to be overweight).
- •Men or women, between the ages of 18 and
- •The subject population is expected to be predominantly made up of women.
排除标准
- •Have concurrent symptoms of bulimia nervosa or anorexia nervosa, including weight loss to at least 15% below the Metropolitan Height/Weight tables.
- •Women who are pregnant, lactating, or of childbearing potential who are not using adequate contraceptive measures. (All women of childbearing potential will have a negative pregnancy test before entering the study).
- •Patients who are displaying clinically significant suicidality or homicidality.
- •Patients who have received psychotherapy or behavioral therapy from a mental health professional as a part of previous treatment for BED for at least 3 months prior to randomization.
- •A DSM-IV diagnosis of substance abuse or dependence (except nicotine abuse or dependence) within the 6 months prior to randomization.
- •A lifetime DSM-IV history of psychosis, mania or hypomania, or dementia.
- •History of any psychiatric and personality disorder (eg, schizotypal and borderline) which might interfere with a diagnostic assessment, treatment, or compliance.
- •Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease which could interfere with diagnosis, treatment, or assessment of BED. Patients should be biochemically euthyroid to enter the study.
- •History of seizures, including febrile seizures in childhood.
- •Patients requiring treatment with any drug which might interact adversely with or obscure the action of the study medication.
- •Clinically relevant abnormal laboratory results, specifically including hypokalemia.
- •Patients who have received monoamine oxidase inhibitors, antipsychotics, lithium, or fluoxetine within four weeks prior to randomization.
- •Patients who have received other psychoactive medications (other than hypnotics) within one week prior to randomization.
- •Patients who have received investigational medications or depot neuroleptics within three months prior to randomization.
- •Patients previously enrolled in this study or have previously been treated with acamprosate.
研究组 & 干预措施
1
Experimental
acamprosate
干预措施: acamprosate (Drug)
2
Placebo Comparator
sugar pill
干预措施: placebo (Other)
结局指标
主要结局
The primary efficacy variable will be change in weekly binge frequency
时间窗: 10 weeks
次要结局
- Secondary efficacy variables will include change in binge day frequency (days during which at least one binge occurs), obsessive-compulsive symptoms of BED, craving for food, depressive symptoms, weight, and BMI(10 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of Acamprosate in Fragile x SyndromeFragile X SyndromeNCT01911455Children's Hospital Medical Center, Cincinnati46
已完成
3 期
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid AlcoholismSchizophreniaAlcohol DependenceNCT00463346Yale University23
已完成
4 期
Atomoxetine in the Treatment of Binge Eating DisorderBinge-eating DisorderNCT00327834Lindner Center of HOPE
已完成
2 期
Sodium Oxybate in the Treatment of Binge Eating DisorderBinge Eating DisorderNCT00514995Lindner Center of HOPE15
已完成
2 期
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist TreatmentBinge-Eating DisorderObesityNCT03063606Yale University31